MOVING MULTIPLE SCLEROSIS CLINICAL STUDIES FORWARD, FASTER
Your CRO partner significantly impacts the success of your multiple sclerosis (MS) clinical research. The development of new medicines targeting MS can take 10 to 15 years from testing in a clinical laboratory to becoming commercially available. For every 10,000 compounds tested, fewer than one or two become licensed treatments. Many are rejected on the grounds of their safety, quality, and efficacy.1
As a full-service CRO with dedicated therapeutic experts in multiple sclerosis research, we have an outstanding track record in starting up and executing MS clinical studies, including beta-interferons, glatiramer acetate monoclonal antibodies, and oral preparations for disease-modifying approaches.